Sydney, Sep 30, 2011 (ABN Newswire) - Agenix Limited (ASX:AGX) confirmed its promising new hepatitis B drug, AGX-1009, shared the same active compound as Gilead’s (NASDAQ:GILD) blockbuster drug, Viread, which is widely used to treat HIV and hepatitis throughout Asia.
